Prenetics Global Limited (NASDAQ:PRE - Free Report) - Cantor Fitzgerald reduced their FY2024 earnings estimates for Prenetics Global in a research note issued on Thursday, March 6th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($3.52) per share for the year, down from their previous forecast of ($3.30). Cantor Fitzgerald has a "Overweight" rating and a $9.00 price target on the stock. The consensus estimate for Prenetics Global's current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global's FY2025 earnings at ($2.12) EPS.
Prenetics Global Trading Down 2.0 %
PRE traded down $0.09 on Monday, reaching $4.40. The stock had a trading volume of 5,381 shares, compared to its average volume of 13,449. Prenetics Global has a fifty-two week low of $2.85 and a fifty-two week high of $7.84. The company has a market capitalization of $53.70 million, a price-to-earnings ratio of -1.10 and a beta of -0.31. The firm has a 50-day moving average of $5.37 and a 200-day moving average of $4.97.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC acquired a new position in Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global at the end of the most recent quarter. Institutional investors and hedge funds own 25.01% of the company's stock.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
See Also
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
